Treatment of colorectal cancer with a simultaneous application of 5-fluorouracil (5-FU)/sodium folinic acid: Results of a large observation study

被引：0
|
作者：
Hofheinz, R. D. [1 ]
Hutschenreuther, U. [1 ]
Sauer, U. [1 ]
Eschenburg, H. [1 ]
Rudolph, R. [1 ]
Tummes, D. [1 ]
Weinberg, R. [1 ]
Guggenberger, D. [1 ]
机构：
[1] Onkol Zentrum, Mannheim, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：I44 / I44
页数：1
相关论文
共 50 条
  • [31] 5-FLUOROURACIL (5-FU), METHYL-CCNU, AND VINCRISTINE IN TREATMENT OF ADVANCED COLORECTAL CANCER - PHASE-2 STUDY UTILIZING WEEKLY 5-FU
    MACDONALD, JS
    KISNER, DF
    SMYTHE, T
    WOOLLEY, PV
    SMITH, L
    SCHEIN, PS
    CANCER TREATMENT REPORTS, 1976, 60 (11): : 1597 - 1600
  • [32] Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer
    Chester, JD
    Dent, JT
    Wilson, G
    Ride, E
    Seymour, MT
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 235 - 237
  • [33] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients
    Terzoli, E
    Garufi, C
    Zappalà, AR
    Vanni, B
    Pugliese, P
    Cappellini, GA
    Aschelter, AM
    Perrone, M
    Giannarelli, D
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (08) : 445 - 452
  • [34] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients
    Edmondo Terzoli
    Carlo Garufi
    Albina Rita Zappalà
    Barbara Vanni
    Patrizia Pugliese
    Giancarlo Antonini Cappellini
    Anna Maria Aschelter
    Maria Perrone
    Diana Giannarelli
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 445 - 452
  • [35] Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell
    Ardil, Buse
    Alper, Mehlika
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (09) : 1109 - 1123
  • [36] Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell
    Buse Ardıl
    Mehlika Alper
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 1109 - 1123
  • [37] NONLINEAR PHARMACOKINETIC CHARACTERISTICS OF 5-FLUOROURACIL (5-FU) IN COLORECTAL-CANCER PATIENTS
    SCHAAF, LJ
    DOBBS, BR
    EDWARDS, IR
    PERRIER, DG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (04) : 411 - 418
  • [38] Predictive profiling of 5-fluorouracil (5-FU) resistance in metastatic colorectal cancer (mCRC).
    Ichikawa, W
    Takahashi, T
    Suto, K
    Okayama, Y
    Toda, E
    Oka, T
    Okayama, S
    Hirayama, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 261S - 261S
  • [39] Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    DelVecchio, M
    Artale, S
    Zunino, F
    Bignami, P
    Magnani, E
    Buzzoni, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 687 - 690
  • [40] WEEKLY REGIMEN OF 5-FU VS 5-FU PLUS INTERMEDIATE DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    MARTONI, A
    CRICCA, A
    GUARALDI, M
    COVIZZI, M
    FARRIS, A
    PANNUTI, F
    ANTICANCER RESEARCH, 1992, 12 (03) : 607 - 612
12345